Every material Form 8-K ELUTIA INC. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Elutia reported third-quarter 2026 net sales of $1.1 million, up 20.4% from $0.9 million a year earlier. Its net loss narrowed to $1.3 million from $3.9 million, but that improvement came from $5.2 million of income from discontinued operations, while the loss from continuing operations widened to $6.5 million from $1.0 million. The company also said it received $26 million in funding in 2026 and plans to submit NXT-41x to the FDA in the fourth quarter of 2026.
Net sales were $1.1 million versus $0.9 million, an increase of 20.4%; cardiovascular sales grew 20%.
Net loss from continuing operations was $6.5 million versus $1.0 million; net loss was $1.3 million versus $3.9 million.
Income from discontinued operations was $5.2 million versus a loss of $2.8 million a year earlier.
Cash and cash equivalents were $29.1 million at September 30, 2026, excluding an $8 million Boston Scientific holdback received October 1, 2026.
Elutia completed the sale of its SimpliDerm breast reconstruction business, which made up substantially all of its Women's Health segment, to Cellution Biologics on August 17, 2026. The company received $7.7 million in cash at closing, subject to post-closing adjustments, with up to $3 million more in contingent payments. The filing says the company's 2025 and first-half 2026 pro forma continuing operations exclude the business, which had accounted for most of its reported net sales.
Net cash received at closing: $7.7 million, subject to post-closing inventory adjustments
Contingent payments of up to $3 million over the next 18 months, tied to technology transfer and commercial milestones
Pro forma six-month 2026 net sales from continuing operations: $2.2 million, versus $5.5 million as reported
Company expects to record an estimated gain of $4.9 million, which is not reflected in the pro forma periods
Elutia reported second quarter 2026 results with net sales down to $2.4 million from $2.7 million, while its net loss narrowed to $7.6 million from $9.6 million. The company said it has secured up to $26 million in additional capital to fund NXT-41x through anticipated FDA clearance and its first full year of commercial launch, without an equity offering, which matters to shareholders because it reduces near-term dilution risk.
Q2 2026 net sales were $2.4 million versus $2.7 million a year earlier, due mainly to a $0.7 million reduction in SimpliDerm revenue from a contract manufacturer production disruption.
Adjusted EBITDA was a loss of $4.6 million versus a loss of $3.0 million in the prior-year quarter.
Up to $26 million of capital includes a $15 million credit facility ($10 million funded at closing) and up to $11 million from the SimpliDerm divestiture.
Cash and cash equivalents were $19.9 million at June 30, 2026, and the company expects the full $8 million BioEnvelope escrow to be released in the fourth quarter of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ELUTIA INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →